Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-Time glucose data may boost healthy habits in prediabetes

NCT ID NCT07423065

Knowledge-focused Sponsor: University of Primorska Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 15, 2026 · Updated 2 times

Summary

This study tests whether people with prediabetes and obesity change their eating and activity habits when they can see their glucose levels in real time versus when the data is hidden. Thirty-four adults will wear a continuous glucose monitor during both an open and a blinded phase. Researchers will compare glucose variability, calorie intake, and weight changes to see if real-time feedback leads to better health outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Continuous glucose monitoring (CGM) device
What this could lead to
If it works, this could show that real-time glucose feedback helps people with prediabetes make healthier choices and lose weight.
What could go wrong
This is a small, early-stage study with only 34 participants, so results may not apply to everyone. The crossover design may also make it harder to see clear effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 34 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18-70 years. * BMI ≥ 27 kg/m² (overweight or obese). * Prediabetes, confirmed by: Impaired fasting glucose (IFG: 5.6-6.9 mmol/L), and/or Impaired glucose tolerance (IGT: 2-hour OGTT glucose 7.8-11.0 mmol/L). * Stable body weight (±3 kg) in the last 3 months. * No current use of antidiabetic or weight-loss medications. * Willingness and ability to wear a CGM device as instructed. * Capacity to provide written informed consent. * Recruitment from the Diabetes Outpatient Clinic, Community Health Center Koper (identified and invited from the clinic's database). Exclusion Criteria: * Diagnosis of type 1 or type 2 diabetes mellitus (fasting glucose ≥ 7.0 mmol/L or HbA1c ≥ 6.5%). * Current or recent (within 3 months) use of: * Any antidiabetic medication (insulin, metformin, GLP-1RA, SGLT2i, etc.), or anti-obesity pharmacotherapy. * Pregnancy, breastfeeding, or planned pregnancy during the study period. * Severe chronic disease that could influence glucose metabolism or study participation (e.g., chronic liver disease, renal failure, active malignancy). * Endocrine disorders affecting metabolism (e.g., untreated thyroid disease, Cushing's syndrome). * Severe psychiatric illness or cognitive impairment limiting adherence or comprehension. * Use of medications known to affect glucose metabolism (e.g., corticosteroids, atypical antipsychotics). * Implanted electronic medical devices (e.g., pacemaker, defibrillator) that may interfere with CGM function. * Known allergy or skin reaction to CGM adhesives or device materials. * Participation in another interventional study within the previous 3 months.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity & overweight are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Behavior glucose intolerance Obesity obesity disorder Overweight prediabetes syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity & overweight Pre diabetic

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department Of endocrinology and diabetes, Medical Faculty, University of Ljubljana

    RECRUITING

    Ljubljana, 1000, Slovenia

  • Diabetes Outpatient Clinic, Community Health Center Koper, Slovenia

    RECRUITING

    Koper, 6000, Slovenia

  • University of Primorska, Faculty of Health Sciences

    RECRUITING

    Izola, 6310, Slovenia

More trials for these conditions

Other studies related to the condition(s) this trial covers.